ArticleEuropean journal of medicinal chemistry2024

Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2.

Julia Velez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.